Accessibility Menu
Biomea Fusion logo

Biomea Fusion(NASDAQ) BMEA

Current Price$1.26
Market Cap$93.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-93%
5 Year-90%
1 Year-29%
1 Month+5%
Biomea Fusion last closing stock price
MetricPriceDate
Last closeUSD 1.292026-07-22
Biomea Fusion stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 1.292026-07-15
1 month+4.88%USD 1.232026-06-22
3 month-31.02%USD 1.872026-04-23
Year to date+4.03%USD 1.242025-12-31
1 year-29.12%USD 1.822025-07-22
3 year-94.01%USD 21.532023-07-21
5 year-90.26%USD 13.242021-07-23
Since inception-92.85%USD 18.602021-04-16

Biomea Fusion Financials at a Glance

Market Cap

$93.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$44.95M

EPS (TTM)

-$0.89

P/E Ratio

-1.45

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Price

$1.26

Volume

0

Open

$1.33

Previous Close

$1.26

Daily Range

$1.26 - $1.33

52-Week Range

$0.87 - $2.99

Estimated Earnings Date

Aug 4, 2026

BMEA News

Foolcom-Featured.png

Biomea Fusion (BMEA) Q2 Loss Drops 44%

Motley Fool Markets TeamAug 5, 2025
growth chart

Why Biomea Fusion Stock Crushed It This Week

George Budwell, PhDMar 30, 2023
doctors white coat healthcare

Why Shares of Biomea Fusion Jumped This Week

James HalleyJan 20, 2023

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biomea Fusion

Biomea Fusion develops new medicines for diabetes and obesity. Its main drug aims to help people manage blood sugar. The company focuses on treatments that may improve life for those with chronic metabolic diseases.

Lab Bench to Bedside: Products and Services

  • Icovamenib (BMF-219): Oral drug in clinical trials for type 2 and type 1 diabetes; also studied for obesity. (0% of revenue; no commercial sales)
  • BMF-650: Early-stage oral drug targeting obesity, designed to mimic natural hormones that regulate appetite. (0% of revenue)
  • BMF-500: Investigational cancer drug, now seeking partners for further development. (0% of revenue)
  • Clinical Trials: Multiple ongoing studies in diabetes and obesity, with over 400 participants dosed to date.
  • Research Focus: All revenue comes from research and development; no product sales yet.

Plot Twists: Growth and Expansion

  • Shifted focus in January 2025 to diabetes and obesity, ending internal cancer research.
  • Launched two new Phase II diabetes trials (COVALENT-211, COVALENT-212) in late 2025.
  • Started Phase I obesity trial (GLP-131) for BMF-650 in 2025.
  • Raised $67.7 million in 2025 through public stock offerings and an at-the-market equity program.
  • No acquisitions or global market entries reported as of December 2025.

What Makes Biomea Fusion Stand Out

The company develops drugs that form permanent bonds with disease targets, a less common approach in diabetes. It keeps full rights to its medicines, allowing flexibility in future partnerships. Biomea Fusion relies on outside manufacturers and has no commercial products yet.

Five Things You Need to Know

  • No revenue from product sales in 2023, 2024, or 2025.
  • Net loss was $61.8 million in 2025, improved 55% from 2024.
  • Research and development expenses fell 52.5% to $61.98 million in 2025.
  • Cash and equivalents were $56.2 million at December 31, 2025.
  • Company needs more funding to continue operations beyond 2025.

Bottom Line

Biomea Fusion shifted its focus to diabetes and obesity in 2025, cutting costs and narrowing its pipeline. The company remains pre-revenue and depends on new funding to advance its drug candidates.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

40

CEO

Michael J. M. Hitchcock, PhD

Website

biomeafusion.com

Headquarters

San Carlos, CA 94063, US

BMEA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-196.72%

Return on Capital

-261.09%

Return on Assets

-96.91%

Earnings Yield

-68.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$93.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

72.30M

Volume

0

Avg. Volume

1.12M

Financials (TTM)

Gross Profit

-$593.00K

Operating Income

-$66.57M

EBITDA

-$46.12M

Operating Cash Flow

-$56.25M

Capital Expenditure

$0.00

Free Cash Flow

-$56.25M

Cash & ST Invst.

$44.69M

Total Debt

$1.24M

Biomea Fusion Performance Analysis

Biomea Fusion annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Biomea Fusion sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Biomea Fusion annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.8095.8%
20232023-12-31USD -3.4423.0%
20242024-12-31USD -3.8311.5%
20252025-12-31USD -1.18-69.1%
Biomea Fusion sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3036.3%
Q32025-09-3047.1%
Q42025-12-31123.6%
Q12026-03-31-366.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$46.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$93.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.33M

N/A

Employees

40

N/A

Net Income

-$12.42M

+57.6%

EBITDA

-$12.37M

+57.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$44.69M

+24.6%

Total Debt

$1.24M

-84.4%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$1.24M

-13.1%

Return on Assets

-96.91%

N/A

Return on Invested Capital

-1.79%

N/A

Free Cash Flow

-$11.67M

+54.5%

Operating Cash Flow

-$11.67M

+54.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ADVMAdverum Biotechnologies, Inc.
$4.36+0.00%
CBUSCibus, Inc.
$1.79-3.76%
RPTXRepare Therapeutics Inc.
$2.65+0.00%
PMVPPMV Pharmaceuticals, Inc.
$1.33+1.53%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
INTCIntel
$102.62-0.03%

Questions About BMEA

What is the current price of Biomea Fusion?

Biomea Fusion is trading at $1.26 per share.

What is the 52-week range for Biomea Fusion?

Over the past 52 weeks, Biomea Fusion has traded between $0.87 and $2.99.

How much debt does Biomea Fusion have?

As of the most recent reporting period, Biomea Fusion reported total debt of $1.24M.

How much cash does Biomea Fusion have on hand?

Biomea Fusion reported $45.06M in cash and cash equivalents in its most recent financial results.

What is Biomea Fusion’s dividend yield?

Biomea Fusion does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services